Merck Cuts Profit Forecast on Acquisition Charges, Beats Revenue Estimates

Merck & Co. (MRK) revised its full-year profit forecast downward on Tuesday, citing charges from two recent acquisitions that weighed on its bottom line. Despite this, the company raised its sales outlook after reporting stronger-than-expected second-quarter revenue. The pharmaceutical giant's stock reacted to the news as investors weighed the impact of the acquisition costs against the revenue beat. Merck's decision to lower profit guidance reflects the financial burden of integrating new assets, while the upward revision in sales suggests robust underlying demand for its products. The company did not specify which acquisitions were responsible for the charges, but the move highlights the strategic investments Merck is making to bolster its pipeline. Analysts noted that the revenue beat was driven by strong performance across key therapeutic areas, though the profit warning tempered enthusiasm. Merck's revised forecast now anticipates lower earnings per share for the full year, while revenue expectations have been raised. The announcement comes amid a competitive landscape in the pharmaceutical industry, where companies are increasingly pursuing acquisitions to offset patent expirations and pipeline gaps. Investors will be watching for further details on the acquisitions and their expected contributions to Merck's long-term growth.